Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 603-373-3 | CAS number: 129909-90-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- Not stated
- Reliability:
- 1 (reliable without restriction)
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to other study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 408 (Repeated Dose 90-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- (1981)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-1 (90-Day Oral Toxicity)
- Version / remarks:
- (1984)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EPA OTS 798.2650 (90-Day Oral Toxicity in Rodents)
- Version / remarks:
- (1989)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- other: JMAFF 59 NohSan No. 4200 (Guidance on toxicology study data for application of agriculture chemical registration) (1985)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 4-amino-N-tert-butyl-5-oxo-3-(propan-2-yl)-4,5-dihydro-1H-1,2,4-triazole-1-carboxamide
- EC Number:
- 603-373-3
- Cas Number:
- 129909-90-6
- Molecular formula:
- C10H19N5O2
- IUPAC Name:
- 4-amino-N-tert-butyl-5-oxo-3-(propan-2-yl)-4,5-dihydro-1H-1,2,4-triazole-1-carboxamide
- Reference substance name:
- Technical Grade MKH 3586
- IUPAC Name:
- Technical Grade MKH 3586
- Details on test material:
- - Name of test material (as cited in study report): Technical Grade MKH 3586
- Physical state: beige powder
- Analytical purity: 97.8 - 98.2%
- Impurities (identity and concentrations):
- Purity test date: June 1994, Dec 1994, Aug 1995
- Lot/batch No.: 17004/93
- Expiration date of the lot/batch: Stability of lot confirmed for the duraton of the study
Constituent 1
Constituent 2
Test animals
- Species:
- rat
- Strain:
- Fischer 344
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 90 days / dietary
- Frequency of treatment:
- Continuous treatment
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
M & F: 0, 100, 250, 500, 1000, 2500, 5000 ppm
Basis:
nominal in diet
- Remarks:
- Doses / Concentrations:
M/F:0, 6.9/7.9, 17.8/20.5, 32.9/38.0, 67.2/77.7, 181.8/200.6, 353.8/396.8 mg/kg/day
Basis:
actual ingested
- No. of animals per sex per dose:
- 30 animals/sex/dose for control and high dose group
15 animals/sex/dose for other groups - Control animals:
- yes, plain diet
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- ca. 500 ppm
- Based on:
- other: liver, thyroid, pancreatic and haematological changes at >1000 ppm
- Sex:
- male/female
- Basis for effect level:
- other: (equivalent to 32.9/38.0 mg/kg/day [M/F])
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
OBSERVATIONS:
Clinical signs of toxicity:
With the exception of increased frequency of food spillage noted in 5000 ppm males and females no other signs were related to exposure to the test material:
Table 7.5.1.2: Incidence of food spillage
Dose (ppm) |
Males |
Females |
0 |
0 |
0 |
100 |
0 |
0 |
250 |
0 |
1 |
500 |
0 |
1 |
1000 |
0 |
1 |
2500 |
0 |
1 |
5000 |
7* |
4* |
*Statistically significant
Mortality:
Mortality in treatment groups was comparable to the concurrent control group.
Bodyweight and bodyweight gain:
Bodyweight gain was unaffected up to 500 ppm, at doses above this a decline in both genders was observed:
Food consumption:
Refer to Table 7.5.1.1 for actual ingested levels of test material. Food consumption and utilisation was unaffected in either sex
Table 7.5.1.3: Bodyweight gain %relative change respective to control group
Dose (ppm) |
Males |
Females |
1000 |
6% |
9% |
2500 |
16% |
14% |
5000 |
19% |
19% |
Opthalmoscopic examination:
No test material related effects were observed.
Urinalysis:
Treatment related increases in urinary pH (500 – 5000 ppm, F), urinary leukocyte numbers (2500 and 5000 ppm, M &F) and urinary protein concentration (5000 ppm, M). The actual toxicological significance of these parameter changes was unknown.
Haematology & clinical chemistry:
Haematology:
Table 7.5.1.4: Summary of haematological changes, gain %relative change respective to control group
Parameter |
Males (ppm) |
Females (ppm) |
increased reticulocyte number |
2500, 5000 |
2500, 5000 |
increased platelet count |
2500, 5000 |
- |
decreased erythrocyte count |
1000, 2500, 5000 |
5000 |
Decreased haemoglobin and haemocrit |
1000, 2500, 5000 |
1000, 2500, 5000 |
Decreased MCV, MCHb |
2500, 5000 |
1000, 2500, 5000 |
These changes observed were consistent with haemolytic anaemia, which was confirmed at necropsy manifest as increased incidence of pigmentation (suggestive of increased destruction of RBC rather than a direct effect on RBC production).
Clinical chemistry: decrease in hepatic aminopyrine N-demethylase activityin males at 1000, 2500 and 5000 ppm. An increase in hepatic p-nitroanisole O-demethylase activity in females (1000, 2500 and 5000ppm) and males (2500 and 5000 ppm) was observed. In light of the findings at necropsy (hepatocytomegaly and karyomegaly) these alterations may have been an adaptive response by the liver to increased need to facilitate metabolism and excrete exogenously administered test material.
An increase in serum thyroxine concentration was observed in males at 1000 ppm and greater, with increases in serum T3in males (1000, 2500, 5000 ppm) and females (2500, 5000 ppm). Refer to sub-chronic 90 day mechanistic study for mode of action.
Sacrifice and Gross Pathology:
No gross lesions observed at necropsy.
Histopathology:
Liver:Increased incidence of hepatocellular changes observed in males (1000, 2500, 5000 ppm) and females (2500, 5000 ppm). The lesion was characterised by both cytomegaly and enlarged cells with granular eosinophilic to occasionally vacuolated cytoplasm and karyomegaly, prominent nuclear enlargement which increased in severity with increasing dose.
Thyroid:Increased incidence of follicular cell hyperplasia was observed at 2500 and 5000 ppm in both genders. The lesion was characterised as minimally enlarged cells, more columnar in type, with increased numbers of active follicles within the central area of the gland as evidenced by increased colloid secretion.
Adrenal: increased incidence of diffuse cytoplasmic vacuolisation of the adrenal cortical epithelial cells observed in males at 5000 ppm, characterised by multiple small vacuoles that gave the cells an overall pale appearance.
Pancreas: increased incidence of cytoplasmic vacuolisation was observed at 5000 ppm in both genders. The lesion was characterised by vacuolar change often associated with dense bodies representative of subtle degeneration or apoptosis in the acinar cells.
Spleen:increased incidence of pigmentation was observed in males (1000, 2500, 5000 ppm) and females (2500, 5000 ppm). special stains suggested deposition of haemosiderin (iron containing pigment derived from Hb of disintegrated RBC).
Bone marrow: atrophy of bone marrow observed in 2500 and 5000 ppm females. Additionally, an increased incidence of atrophy or inactivity of the growth plate was observed in 2500 and 5000 ppm females.
Organ weights:
Test material related increases in liver weights were observed in both males and females of the high dose group where liver weights were 43 (M) and 41% (F) higher than respective control groups.
Applicant's summary and conclusion
- Conclusions:
- Based on the results of this study, the NOAEL was 500 ppm (32.9 mg/kg/day for males and 38.0 mg/kg/day for females) based on liver, thyroid, pancreatic and haematological changes observed at doses of 1000 ppm and greater.
- Executive summary:
Seven groups, 6 treatment and 1 control group of 30 animals/dose/sex, for the control and high dose groups or 15 animals/sex/group for all other groups were fed MKH 3586 in the diet for 13 consecutive weeks. Dietary concentrations of 0, 100, 250, 500, 1000, 2500 or 5000 ppm were administered, equivalent to compound intakes of 0, 6.9, 178, 32.9, 67.2, 181.8 and 353.8 mg/kg/day for males and 0, 7.9, 20.5, 38.0, 77.7, 200.6, 396.8 mg/kg/day for females respectively. Following the exposure period of the study, 15 animals/sex of the control and high dose groups were placed on control diet (recovery period) for a further 4 weeks to assess any reversible effects.
Test material related changes were in the liver (hepatocytomegaly and karyomegaly), pancreas (cytoplasmic vacuolisation), spleen (pigmentation due to deposition of haemosiderin) and bone marrow (atrophy of the marrow along with inactivity of the growth plate). These changes occurred at doses of 1000 ppm and greater. Haematological changes were representative of haemolytic anaemia, suggestive of increased destruction of RBC, rather than a direct effect on RBC production.
Based on the results of this study, the NOAEL was 500 ppm (32.9 mg/kg/day for males and 38.0 mg/kg/day for females) based on liver, thyroid, pancreatic and haematological changes observed at doses of 1000 ppm and greater.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.